TIMI

From WikiMD's WELLNESSPEDIA

TIMI or Thrombolysis in Myocardial Infarction is a clinical trial group funded by the National Heart, Lung, and Blood Institute to investigate the treatment of acute myocardial infarction. This group has conducted several large, multicenter trials that have led to changes in medical guidelines and practice.

History[edit]

The TIMI Study Group was established in 1984 at the Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, to conduct the original TIMI Trial. The group has since grown to include over 50 clinical research professionals and has conducted over 50 clinical trials involving more than 200,000 patients worldwide.

TIMI Score[edit]

The TIMI Score is a tool used by healthcare professionals to assess the risk of death and ischemic events in patients with unstable angina or non-ST elevation myocardial infarction. The score is based on seven variables, each of which is associated with an increased risk of adverse outcomes. The higher the TIMI Score, the greater the risk.

TIMI Trials[edit]

The TIMI Trials have investigated a variety of treatments for acute myocardial infarction, including thrombolytic therapy, antiplatelet therapy, anticoagulant therapy, and invasive strategies. The results of these trials have informed the development of guidelines for the treatment of acute myocardial infarction.

See Also[edit]

References[edit]


External Links[edit]


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=TIMI&oldid=6531390"